Aphexda Approved in Us to Improve Autologous Stem Cell Transplants

Aphexda Approved in Us to Improve Autologous Stem Cell Transplants

Aphexda (motixafortide) from BioLineRx has been given U.S. approval in conjunction with filgrastim (G-CSF) to facilitate autologous hematopoietic stem cell transplant (AHSCT) for multiple myeloma patients. Effective bloodstream mobilisation of...

Fill out our treatment application form. The form is designed to help us understand your treatment goals.

Click on the Icons to See the Various Steps of Our Patient Treatment Process